Courses

Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE
Cardiology

Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE

This 0.5-hour, Whiteboard Animation Webcast is designed to review clinical trial and deal-world data for DOAC and other anticoagulation therapeutics for VTE. A majority of new diagnoses of VTE are made by primary care professionals. Evidence-based guidelines for the management of VTE include the most recent updates from the American Society of Hematology (ASH, 2020), the European Society of Cardiology ...
View Course
Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis
Neurology

Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis

About 85% of patients with generalized myasthenia gravis (gMG)--an autoimmune disease of the neuromuscular junction caused by antibodies that attack components of the postsynaptic membrane, impair neuromuscular transmission, and therefore cause weakness and fatigue of skeletal and bulbar muscles--have demonstrable IgG autoantibodies.  These autoantibodies exert a direct pathogenic effect that results in impaired neuromuscular transmission.  Most currently available treatments, including ...
View Course
Strategies to Address Unmet Needs and Care Delivery Disparities in the Management of Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
Nephrology

Strategies to Address Unmet Needs and Care Delivery Disparities in the Management of Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

Many CKD patients also experience complex and compounding burdens of disease, particularly once they progress to the stage of requiring hemodialysis. This notably includes anemia (aCKD), which is associated with a reduced quality of life and increased morbidity and mortality. Encouraging clinical trial data have recently emerged for hypoxia-inducible, factor prolyl hydroxylase inhibitor (HIF-PHI) therapeutics for patients on dialysis for ...
View Course
Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis
Neurology

Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis

Patients with generalized myasthenia gravis (gMG) experience significant and heterogeneous symptomatology, placing a substantial burden on their quality of life including physical, emotional, and work/financial aspects. Recent clinical trial data are showing that the utilization of individualized dosing including holding treatment during periods of stability can be effective and safe. It is important for clinicians to assess these data and ...
View Course
Accurate Diagnosis and Guideline-Driven Individualized Treatment Plans to Manage Patients with Non-Tuberculous Mycobacterial Lung Disease
Pulmonology

Accurate Diagnosis and Guideline-Driven Individualized Treatment Plans to Manage Patients with Non-Tuberculous Mycobacterial Lung Disease

This program is derived from a lecture delivered at the 2023 Eastern Pulmonary Conference. The expert faculty, Drs. Reynold A. Panettieri Jr. and Anne E. O’Donnell, will highlight recent advances in the treatment and management of patients with non-tuberculous mycobacterial lung disease. The faculty will utilize a case-based approach to analyze current clinical trial data of amikacin-based inhalation therapeutics for ...
View Course
Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG
Neurology

Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG

Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology. Both incidence and prevalence of the disease have increased over the years because of greater awareness of MG, better application of diagnostic testing, and better quality of epidemiologic studies. Corticosteroids were introduced as treatment for MG in the 1950s ...
View Course

Advances in Disease Management of Generalized Myasthenia Gravis
Neurology

Advances in Disease Management of Generalized Myasthenia Gravis

This CME program will highlight recent advances in disease management of generalized myasthenia gravis (MG). The expert faculty, led by Dr. Vera Bril, will first outline the pathophysiology of myasthenia gravis, detailing epidemiology, pathogenesis and the case for targeted treatments. Following, current clinical trial data for FcRn inhibitors in MG will be analyzed, including a review of mechanisms of action ...
View Course
Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients
Nephrology

Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients

Anemia is a common complication in CKD (aCKD) and is associated with a reduced quality of life and increased morbidity and mortality. The mechanisms involved in aCKD are diverse and complex. They include a decrease in endogenous erythropoietin production, absolute and/or functional iron deficiency, and inflammation with increased hepcidin levels, among others. Patients are most commonly managed with oral or ...
View Course
Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy
Cardiology

Optimizing Echocardiographic and CMR Assessment in the Diagnosis and Management of Hypertrophic Cardiomyopathy

This CME program, derived from content presented at the European Association of Cardiovascular Imaging Annual Congress EACVI 2023 in Barcelona, Spain, will highlight how to optimize echocardiographic and CMR assessment in the diagnosis and management of hypertrophic cardiomyopathy. In hypertrophic cardiomyopathy, multimodality imaging is crucial to confirm diagnosis, assess for presence and mechanism of left ventricular outflow tract obstruction, and ...
View Course

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Oncology

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This CME program, derived from content presented at the AACR Annual Meeting 2023 in Orlando, FL, will highlight the advancing role of PARP inhibitor combination therapies to improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). The expert faculty, led by Dr. Alan Tan, will first review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen ...
View Course